CBPO [China Biologic Products] 8-K: (Original Filing)

[China Biologic to Attend the 34th Annual J.P. Morgan Healthcare Conference BEIJING, China – January 4, 2016 – Management will present at the conference on Wednesday, January 13, 2016 at 10:30am Pacific Time. For additional information or interest in meeting with management, please contact your J.P. Morgan institutional sales representative. About China Biologic Products, Inc. China Biologic Products, Inc. (NASDAQ:] [34 th Annual J.P . Morgan Healthcare Conference January 2016 China Biologic Products, Inc. (NASDAQ: CBPO) Creating Miracles in Life Capital Structure Price: $142.46 (12/31/2015 ) Market Capitalization: $3.8 billion 52 - Week Range: $64.36 - $143.21 Shares Outstanding : 26.5 mm Selected 9M15 Financials Revenue: $228.2 mm, up 23.2% y - o - y Gross Profit: $148.7 mm, up] []

CBPO [China Biologic Products] 8-K: China Biologic to Attend the 34th Annual J.P.

[China Biologic to Attend the 34th Annual J.P. Morgan Healthcare Conference BEIJING, China – January 4, 2016 – Management will present at the conference on Wednesday, January 13, 2016 at 10:30am Pacific Time. For additional information or interest in meeting with management, please contact your J.P. Morgan institutional sales representative. About China Biologic Products, Inc. China Biologic Products, Inc. (NASDAQ:] [34 th Annual J.P . Morgan Healthcare Conference January 2016 China Biologic Products, Inc. (NASDAQ: CBPO) Creating Miracles in Life Capital Structure Price: $142.46 (12/31/2015 ) Market Capitalization: $3.8 billion 52 - Week Range: $64.36 - $143.21 Shares Outstanding : 26.5 mm Selected 9M15 Financials Revenue: $228.2 mm, up 23.2% y - o - y Gross Profit: $148.7 mm, up] []

CBPO [China Biologic Products] SC 13G: (Original Filing)

[(Name of Issuer) Common Stock 16938C106 (CUSIP Number) October 28, 2015 (Date of Event Which Requires Filing of this Statement) ☐ Rule 13d-1(b) ☑ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent]

CBPO [China Biologic Products] SC 13G: (Name of Issuer) Common Stock 16938C106 (CUSIP Number)

[(Name of Issuer) Common Stock 16938C106 (CUSIP Number) October 28, 2015 (Date of Event Which Requires Filing of this Statement) ☐ Rule 13d-1(b) ☑ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent]

CBPO [China Biologic Products] 8-K: (Original Filing)

[FOR RELEASE November 3, 2015 China Biologic Reports Financial Results for the Third Quarter of 2015 3Q15 Total Sales Up 14.4% YoY to $78.8 Million 3Q15 Non-GAAP Net Income Up 23.6% YoY to $26.2 Million 9M15 Total Sales Up 23.2% YoY to $228.2 Million 9M15 Non-GAAP Net Income Up 31.1% YoY to $79.7 Million Raises Forecast for FY15 Non-GAAP Adjusted] []

CBPO [China Biologic Products] 8-K: FOR RELEASE November 3, 2015 China Biologic Reports

[FOR RELEASE November 3, 2015 China Biologic Reports Financial Results for the Third Quarter of 2015 3Q15 Total Sales Up 14.4% YoY to $78.8 Million 3Q15 Non-GAAP Net Income Up 23.6% YoY to $26.2 Million 9M15 Total Sales Up 23.2% YoY to $228.2 Million 9M15 Non-GAAP Net Income Up 31.1% YoY to $79.7 Million Raises Forecast for FY15 Non-GAAP Adjusted] []

CBPO [China Biologic Products] 10-Q: (Original Filing)

[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Ming Yang Chief Financial Officer (Principal Financial Officer)]

CBPO [China Biologic Products] 8-K: (Original Filing)

[FOR RELEASE October 20, 2015 China Biologic Received Operating Permit for New Branch Collection Facility in Shandong Province BEIJING, China – October 20, 2015 – This new branch collection facility will operate under the Company’s Ningyang plasma collection station and cover the collection territory of Zaozhuang City, which has a population of 3.8 million and offers a reliable source of] []

Skip to toolbar